Form 4: Corvus Pharmaceuticals Director Acquires Stock Options

Director Terry P. Gould reports acquisition of stock options in Corvus Pharmaceuticals, indirectly held through Adams Street Partners.

Summary

• On June 13, 2024, Terry P. Gould, a director of Corvus Pharmaceuticals, acquired 15,000 stock options with an exercise price of $2.12.
• The options vest on the earlier of the first anniversary of the grant date or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
• Gould indirectly holds 3,275,616 shares of common stock through various Adams Street funds.
• Adams Street Partners, LLC, as the managing member of the general partner of the general partner of each of AS 2011, AS 2012, AS 2013, AS 2014, AS 2015, AS 2016, AS 2017, AS 2018 and ASVG VI (collectively the 'Funds'), may be deemed to beneficially own the shares held by the Funds.
• Mr. Gould is deemed to hold the option for the benefit of the Funds.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing regarding stock option grants, which is neutral in sentiment.

Industry Context

This filing is a routine disclosure related to insider transactions and provides insight into the compensation structure for board members. It is common for directors to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates